CACNA1C as a Prognostic Biomarker and Therapeutic Target in High-Grade Serous Ovarian Cancer: Clinical Validation and Molecular Dynamics of Nifedipine Blockade
High-Grade Serous Ovarian Cancer (HGSOC) is the most lethal gynecological malignancy due to aggressive growth, widespread metastases, and high intra-tumoral heterogeneity. Poor prognosis is largely due to late diagnosis, hence there is an urgent need to identify novel biomarkers for screening, diagnosis, and monitoring. Here, we propose the voltage-dependent calcium channel hCaV1.2 encoded by CACNA1C as a potential biomarker and therapeutic target in HGSOC. Using IHC analysis for ten ovarian cancer patients, cytotoxicity assay, TCGA gene expression and survival analyses, homology modeling, molecular docking, Calcium channel membrane assembly and molecular dynamics simulations, we tested CACNA1Cs role in HGSOC progression and the effect of blocking on cancer cell survival. We show that nifedipine (NIFE), a calcium channel blocker (CCB), had a tumor suppressive effect based on binding models predicted by three-dimensional computer assisted molecular modeling and in vitro validation using human HGSOC cell line. Using The Cancer Genome Atlas ovarian public cohort, we found CACNA1C mRNA expression strongly correlated with poor patient survival for late-stage and metastasis than primary. We also show strong correlation of CACNA1C protein expression using immunohistochemistry correlating with COH ovarian carcinomas patients disease progression. This research demonstrates that targeting HGSOC via CCBs may be therapeutically beneficial. By establishing further in vitro, in vivo, and clinical trials using FDA approved NIFE may be repurposed to target CACNA1C for HGSOC. Novelty and ImpactHigh-grade serous ovarian cancer (HGSOC) remains lethal due to late diagnosis and drug resistance. This study identifies CACNA1C (Cav1.2) as a novel prognostic biomarker and therapeutic target in HGSOC, showing that elevated expression correlates with metastatic/recurrent disease and poor survival. Using molecular dynamics and in vitro models, we demonstrate that the FDA-approved calcium channel blocker nifedipine binds stably to Cav1.2 and suppresses tumor cell growth more effectively than cisplatin. These findings support repurposing nifedipine for biomarker-driven HGSOC therapy. Translational RelevanceLate diagnosis and progressive relapses significantly contribute to the poor prognosis of ovarian cancer. Identification of a tumor biomarker that can be used for screening, diagnosis, and monitoring is critical for improving clinical outcome. Our findings demonstrate that CACNA1C is a viable diagnostic marker for HGSOC and that its blockade with CCBs reduces tumor progression, highlighting their therapeutic potential.